Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-05-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
第三届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting agenda item about the use of raised funds to provide loans to subsidiaries for project implementation. It references regulatory rules and company bylaws but does not contain financial statements or detailed financial data. The document is focused on board-related matters and independent director opinions on corporate governance issues. It is not an annual report, audit report, earnings release, or any financial report. It is also not a simple announcement or certification but a formal opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2023-05-17 Chinese
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 Annual General Meeting (AGM) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of the shareholder votes on various proposals. The document does not contain financial statements or detailed financial performance data but focuses on the legality and compliance of the AGM process and voting results. It is not the actual Annual Report or financial report but a legal opinion related to the AGM. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official results from shareholder votes at the AGM.
2023-05-15 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes voting results on various proposals such as the 2022 annual report, board and supervisory reports, financial statements, profit distribution, and other corporate matters. The document also confirms the legality and validity of the meeting and voting procedures, supported by a legal opinion. The content focuses on the AGM meeting details and voting outcomes rather than the full annual report or financial statements themselves. The document length is 4470 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-15 Chinese
关于首次公开发行网下配售限售股上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the listing and circulation of restricted shares from its initial public offering (IPO). It details the number of shares being unlocked, the date of circulation, shareholder commitments, and compliance with regulatory requirements. The document references regulatory approvals and stock exchange rules but does not contain financial statements or detailed financial performance data. It is primarily an announcement about the lifting of restrictions on shares and their availability for trading. The document length is 2909 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance, not a full financial report or other specific filing type.
2023-05-08 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from a sponsoring institution (中信证券股份有限公司) regarding the unlocking and circulation of restricted shares from a company's initial public offering (IPO) on the Shenzhen Stock Exchange. It details the number of shares, shareholder commitments, compliance with regulatory requirements, and the schedule for lifting restrictions on these shares. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to share circulation and compliance verification. It does not contain financial statements or detailed financial analysis. Given the nature of the content, it fits best under Regulatory Filings (RNS), as it is a compliance and regulatory disclosure about share circulation post-IPO.
2023-05-08 Chinese
关于举行2022年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance explanation meeting (业绩说明会) for the 2022 fiscal year. It references the prior disclosure of the 2022 Annual Report and its summary but does not contain the report itself or detailed financial data. The document invites investors to participate in the meeting and submit questions. The length is short (862 characters), and the content is clearly an announcement of an event related to discussing the annual report, not the report itself. Therefore, it fits the category of an Investor Presentation (IP) announcement or a notice about a performance explanation meeting. Given the definitions, this is best classified as an Investor Presentation (IP) because it is a detailed presentation event focusing on financials and company performance for investors.
2023-04-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.